Growth Hormone News and Research RSS Feed - Growth Hormone News and Research

Growth hormone (GH) is a protein-based peptide hormone. It stimulates growth, cell reproduction and regeneration in humans and other animals. Growth hormone is a 191-amino acid, single-chain polypeptide that is synthesized, stored, and secreted by the somatotroph cells within the lateral wings of the anterior pituitary gland.
New, simpler way for encapsulation-free controlled protein release

New, simpler way for encapsulation-free controlled protein release

A U of T Engineering team has designed a simpler way to keep therapeutic proteins where they are needed for long periods of time. The discovery is a potential game-changer for the treatment of chronic illnesses or injuries that often require multiple injections or daily pills. [More]
Researchers find way to selectively deliver drugs to placenta without harming fetus

Researchers find way to selectively deliver drugs to placenta without harming fetus

Nearly 10 percent of babies born in the United States are born premature, according to the March of Dimes. The underlying cause of many complications during pregnancy is often a poorly functioning placenta, the organ that nourishes and maintains the fetus. [More]
Combining aromatase inhibitors with growth hormone may help short adolescent boys grow taller

Combining aromatase inhibitors with growth hormone may help short adolescent boys grow taller

Aromatase inhibitors, when used for up to three years in combination with growth hormone, may effectively and safely help very short adolescent boys grow taller, new research suggests. The study results will be presented Sunday, April 3, at ENDO 2016, the annual meeting of the Endocrine Society in Boston. [More]
Researchers clarify potential transmissibility of Alzheimer's disease

Researchers clarify potential transmissibility of Alzheimer's disease

MedUni Vienna researchers have published the results of a clarifying research study on the potential transmissibility of Alzheimer's disease. Although the protein associated with Alzheimer's disease, amyloid-β, might be transmissible under very unusual circumstances, this does not go along with a transmission of the clinical manifestation of Alzheimer's disease. The affected persons develop no clinical symptoms of the disease. [More]
RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

The U.S. Food and Drug Administration has approved IMBRUVICA (ibrutinib) capsules for treatment-naïve patients with chronic lymphocytic leukemia (CLL). [More]
Intestinal microbiota necessary for optimum postnatal growth

Intestinal microbiota necessary for optimum postnatal growth

The intestinal microbiota is necessary to ensure optimum postnatal growth and contributes to determining the size of adult individuals, notably in the event of undernutrition. [More]
Favourable safety, disease control for proton radiotherapy in paediatric medulloblastoma

Favourable safety, disease control for proton radiotherapy in paediatric medulloblastoma

Proton radiotherapy has an acceptable safety and disease control profile in paediatric medulloblastoma patients, according to research published in The Lancet Oncology. [More]
Study provides new insight into complex interchange that can raise blood levels of fat in type 1 diabetes

Study provides new insight into complex interchange that can raise blood levels of fat in type 1 diabetes

Researchers have new insight into the complex interchange that can raise blood levels of unhealthy lipids, or fat, in type 1 diabetes, and early evidence that a drug under study to block cancer cell growth can restore healthier levels. [More]
Proton beam therapy safe for treating childhood brain cancer medulloblastoma

Proton beam therapy safe for treating childhood brain cancer medulloblastoma

Proton beam therapy--a more precise form of radiotherapy--to treat the childhood brain cancer medulloblastoma appears to be as safe as conventional radiotherapy with similar survival rates, according to new research published in The Lancet Oncology journal today. [More]
Study focuses on parents' perceptions of risks, benefits of treating children with short stature

Study focuses on parents' perceptions of risks, benefits of treating children with short stature

A new study led by pediatric endocrinologist Adda Grimberg, M.D., of The Children's Hospital of Philadelphia, proposes to reframe the debate. "We set out to answer a new question," said Grimberg. "What are the factors, perceived or real, that drive some families to seek medical care for short stature?" [More]
Rotation model provides explanation of ligand activation mechanism of dimeric receptors

Rotation model provides explanation of ligand activation mechanism of dimeric receptors

"This 'rotation model', which made the cover of BioEssays, represents a true paradigm shift in the membrane receptor field," stated Prof. Pierre De Meyts, a renowned researcher of insulin and receptor binding for almost half a century and one of the reviewers of the paper by Prof. Ichiro Maruyama, the head of the Information Processing Biology Unit at Okinawa Institute of Science and Technology Graduate University. [More]
Latitude, summer daylight exposure make difference in results for children treated with growth hormone

Latitude, summer daylight exposure make difference in results for children treated with growth hormone

The rate of growth in children varies with the season while higher latitude and greater summer daylight exposure makes a significant difference in results for children treated with growth hormone, according to new research from The University of Manchester. [More]
Frost & Sullivan honours recipients of 2015 Excellence in Best Practices Awards

Frost & Sullivan honours recipients of 2015 Excellence in Best Practices Awards

On Thursday, October 22, Frost & Sullivan honoured recipients of its 2015 Excellence in Best Practices Awards Banquet in Monaco. With a festive ambiance and exciting Awards, the event brought together top executives to celebrate their success. [More]
Paradigm failure is primary reason for lack of progress in cancer research, says cancer biologist

Paradigm failure is primary reason for lack of progress in cancer research, says cancer biologist

A recent publication, which received sustained media attention, claimed that most cancers are just “bad luck”. Its authors stated that only about one-third of cancer mutations are caused by known lifestyle or environmental factors. [More]
No lasting metabolic health costs from combined GH and GnRH analogue therapy

No lasting metabolic health costs from combined GH and GnRH analogue therapy

Gonadotropin-releasing hormone analogue given alongside growth hormone during puberty in order to increase adult height does not have long-term metabolic health consequences in children born small for gestational age, research shows. [More]
Neuroendocrine sequelae common after paediatric optic gliomas

Neuroendocrine sequelae common after paediatric optic gliomas

Neuroendocrine sequelae are common following paediatric low-grade gliomas affecting the optic pathway, hypothalamus and suprasellar areas and are influenced by tumour location and treatment choice, a study shows. [More]
Signs of Alzheimer’s found in growth hormone patients

Signs of Alzheimer’s found in growth hormone patients

People may be able to contract Alzheimer’s disease during certain medical procedures in the same way that Creutzfeldt-Jakob disease (CJD) is transmitted, suggest researchers from University College London. [More]
Ascendis Pharma's total revenue decreases 50% to €1.9 million in second quarter 2015

Ascendis Pharma's total revenue decreases 50% to €1.9 million in second quarter 2015

Ascendis Pharma A/S, a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced financial results for the three and six months ended June 30, 2015. [More]
FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

Chiasma, Inc., a U.S. late-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application (NDA) for the marketing and sale of octreotide capsules, an oral drug proposed for the maintenance therapy of adult patients with acromegaly. [More]
Research: Critical aspects of human genome's regulatory program encoded by genomic sequence elements

Research: Critical aspects of human genome's regulatory program encoded by genomic sequence elements

Since the classical studies of Jacob and Monod in the early 1960s, it has been evident that genome sequences contain not only blueprints for genes and the proteins that they encode, but also the instructions for a coordinated regulatory program that governs when, where and to what extent these genes and proteins are expressed. [More]
Advertisement
Advertisement